Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma.

IF 2.3 4区医学 Q3 ALLERGY Asian Pacific journal of allergy and immunology Pub Date : 2024-03-01 DOI:10.12932/AP-130520-0842

Aphiradee Theeranawakam, Sasijit Vejbaesya, Archrob Khuhapinant, Pradermchai Sae-Tam

{"title":"Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma.","authors":"Aphiradee Theeranawakam, Sasijit Vejbaesya, Archrob Khuhapinant, Pradermchai Sae-Tam","doi":"10.12932/AP-130520-0842","DOIUrl":null,"url":null,"abstract":"Background: Natural killer (NK) cells have been implicated in the immune response against multiple myeloma (MM) cells. Killer cell immunoglobulin-like receptors (KIRs) regulate NK cell activity by recognizing specific human leukocyte antigen (HLA) class I as ligands.Objective: To investigate the association of KIR genes and ligands with MM in the Thai population.Methods: KIR gene polymorphisms and their HLA ligands were investigated in 66 Thai patients with MM and 200 healthy controls.Results: The frequencies of KIR3DL1 and 2DS4 were significantly lower in myeloma patients than in controls (P = 0.02). The frequencies of KIR3DL1, 2DS4, 2DL1 with C2, and 3DL1 with Bw4 were significantly higher in the patients achieving > very good partial response (VGPR) than those achieving ≤ VGPR after treatment with bortezomib (P = 0.009, 0.009, 0.01, and 0.02, respectively).Conclusions: This study suggests the association of KIR genes with the protection against MM and the association of inhibitory KIR and ligands with the response to treatment in MM.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"77-80"},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-130520-0842","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Natural killer (NK) cells have been implicated in the immune response against multiple myeloma (MM) cells. Killer cell immunoglobulin-like receptors (KIRs) regulate NK cell activity by recognizing specific human leukocyte antigen (HLA) class I as ligands.

Objective: To investigate the association of KIR genes and ligands with MM in the Thai population.

Methods: KIR gene polymorphisms and their HLA ligands were investigated in 66 Thai patients with MM and 200 healthy controls.

Results: The frequencies of KIR3DL1 and 2DS4 were significantly lower in myeloma patients than in controls (P = 0.02). The frequencies of KIR3DL1, 2DS4, 2DL1 with C2, and 3DL1 with Bw4 were significantly higher in the patients achieving > very good partial response (VGPR) than those achieving ≤ VGPR after treatment with bortezomib (P = 0.009, 0.009, 0.01, and 0.02, respectively).

Conclusions: This study suggests the association of KIR genes with the protection against MM and the association of inhibitory KIR and ligands with the response to treatment in MM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

泰国多发性骨髓瘤患者的杀伤细胞免疫球蛋白样受体。

背景：自然杀伤（NK）细胞与针对多发性骨髓瘤（MM）细胞的免疫反应有关。杀伤细胞免疫球蛋白样受体（KIR）通过识别作为配体的特异性人类白细胞抗原（HLA）I类来调节NK细胞的活性：研究泰国人群中 KIR 基因和配体与 MM 的关系：方法：在 66 名泰国 MM 患者和 200 名健康对照者中调查 KIR 基因多态性及其 HLA 配体：结果：骨髓瘤患者 KIR3DL1 和 2DS4 的频率明显低于对照组（P = 0.02）。KIR3DL1、2DS4、2DL1与C2和3DL1与Bw4的频率在硼替佐米治疗后达到>很好部分反应（VGPR）的患者中明显高于达到≤VGPR的患者（P分别为0.009、0.009、0.01和0.02）：这项研究表明，KIR 基因与 MM 的保护作用有关，而抑制性 KIR 和配体与 MM 的治疗反应有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asian Pacific journal of allergy and immunology 医学-过敏

CiteScore

12.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.